Current Cancer Drug Targets
Title: Erratum
Volume: 8 Issue: 4
Export Options
About this article
Cite this article as:
Erratum, Current Cancer Drug Targets 2008; 8 (4) . https://dx.doi.org/10.2174/156800908784533472
DOI https://dx.doi.org/10.2174/156800908784533472 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
11
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genetic Abnormalities in Prostate Cancer
Current Genomics HPV Viral Activity by mRNA-HPV Molecular Analysis to Screen the Transforming Infections in Precancer Cervical Lesions
Current Pharmaceutical Biotechnology MicroRNAs in the Pathobiology of Multiple Myeloma
Current Cancer Drug Targets Oxidative Stress in Tumor Angiogenesis - Therapeutic Targets
Current Pharmaceutical Design Targeting the Ubiquitin-Mediated Proteasome Degradation of p53 for Cancer Therapy
Current Pharmaceutical Design Protein Phosphatase 2A as a Potential Target for Treatment of Adult T Cell Leukemia
Current Cancer Drug Targets Gene Expression Profiles Induced by Amphetamine and Phencyclidine; Novel Targets for the Treatment of Drug Psychosis and Schizophrenia
Medicinal Chemistry Reviews - Online (Discontinued) BRAF Inhibitor Therapy for Melanoma, Thyroid and Colorectal Cancers: Development of Resistance and Future Prospects
Current Cancer Drug Targets Novel Therapeutic Approaches to Regulate Human Dihydrofolate Reductase Activity and Expression
Current Enzyme Inhibition Seocalcitol (EB 1089) A Vitamin D Analogue of Anti-cancer Potential. Background, Design, Synthesis, Pre-clinical and Clinical Evaluation
Current Pharmaceutical Design Oncogenic Signalling Networks and Polypharmacology as Paradigms to Cope with Cancer Heterogeneity
Current Proteomics Mechanisms of Drug Resistance in Cancer Chemotherapy: Coordinated Role and Regulation of Efflux Transporters and Metabolizing Enzymes
Current Pharmaceutical Design Nucleic Acid-Based Aptamers: Applications, Development and Clinical Trials
Current Medicinal Chemistry Targeting the BRCA1/2 Tumor Suppressors
Current Drug Targets Targeting the G2/M Transition for Antitumor Therapy
Letters in Drug Design & Discovery MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Ovarian Cancer
Recent Patents on Biomarkers Management of Incidental Findings in the Era of Next-generation Sequencing
Current Genomics Anal Cancer: Focus on HIV-Positive Patients in the HAART Era
Current HIV Research Genetic and Epigenetic Heterogeneity in Cancer: The Ultimate Challenge for Drug Therapy
Current Drug Targets Keeping the Balance Between Proliferation and Differentiation:The Primary Cilium
Current Genomics